ZUMA-2 Trial: Mantle Cell Lymphoma
In the ZUMA-2 trial, Kite Pharma is also evaluating the treatment of relapsed/refractory mantle cell lymphoma (MCL) with KTE-C19. MCL is an aggressive B-cell lymphoma comprising roughly 6% of non-Hodgkin lymphomas.
In the ongoing ZUMA-2, the main objective is to assess safety and efficacy of KTE-C19, as measured by overall response rate. Secondary endpoints include duration of response, progression-free survival, overall survival, pharmacokinetics, pharmacodynamics, and predictive biomarker analyses. The study is planned at approximately 25 sites in the United States and European Union.
If patients or practitioners would like more details about ongoing clinical trials, information can be found at the National Cancer Institute’s clinical trials website.
